uniQure (NASDAQ:QURE) Upgraded to Hold at Barclays

Barclays upgraded shares of uniQure (NASDAQ:QURE) to a hold rating in a research report released on Tuesday,Zacks.com reports.

Other analysts have also issued research reports about the company. Leerink Partners dropped their target price on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. HC Wainwright dropped their price objective on shares of uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Wells Fargo & Company dropped their price target on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. The Goldman Sachs Group cut their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Finally, Royal Bank Of Canada reduced their target price on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, uniQure has an average rating of “Moderate Buy” and a consensus target price of $58.33.

uniQure Stock Up 1.2%

QURE stock traded up $0.27 during trading hours on Tuesday, reaching $23.29. 205,015 shares of the stock were exchanged, compared to its average volume of 1,862,796. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -5.29 and a beta of 0.68. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50. The firm’s 50-day moving average is $23.81 and its 200-day moving average is $28.31.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, equities research analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Activity

In other uniQure news, Director Robert Gut sold 25,613 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director owned 20,439 shares in the company, valued at $557,575.92. The trade was a 23.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 102,247 shares of company stock worth $2,839,298. 4.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

Hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP raised its position in shares of uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of uniQure during the second quarter valued at about $117,000. Aberdeen Group plc increased its position in shares of uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after acquiring an additional 535,163 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of uniQure in the 2nd quarter worth about $872,000. Finally, Teacher Retirement System of Texas bought a new position in shares of uniQure in the second quarter valued at approximately $151,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.